<DOC>
	<DOCNO>NCT02289690</DOCNO>
	<brief_summary>The study seek assess efficacy veliparib ( ABT-888 ) combination carboplatin etoposide participant extensive disease small cell lung cancer ( ED SCLC ) . ED SCLC define herein SCLC except disease confine hemithorax origin , without involvement regional lymph node , include ipsilateral contralateral mediastinal , ipsilateral contralateral mediastinal , ipsilateral supraclavicular node</brief_summary>
	<brief_title>Dose Escalation Double-blind Study Veliparib Combination With Carboplatin Etoposide Treatment-naive Extensive Stage Disease Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>1 . Subject histologically cytologically confirm extensivestage disease SCLC newly diagnose chemotherapy naive 2 . Phase 1 ONLY : histologically cytologically confirm advanced/metastatic solid tumor carboplatin/etoposide treatment consider appropriate . 3 . Subject Phase 2 : must measurable disease per RECIST 1.1 . 4 . Subjects ED SCLC must consent provide available archived formalin fix paraffin embed ( FFPE ) tissue sample SCLC lesion ( primary metastatic ) central review biomarker analysis . 5 . Subject Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 . 6 . Subject must adequate hematologic , renal hepatic function . 1 . Phase 1 ONLY : Subject prior anticancer therapy : Hormonal , nonmyelosuppressive , biologic , target , immune therapy ( must complete ≥ 4 week prior Cycle 1 Day 2 ) . One line cytotoxic chemotherapy ( must complete ≥ 4 week prior Cycle 1 Day 2 ) . Adjuvant/neoadjuvant radiotherapy ( must complete ≥ 12 month prior Cycle 1 Day 2 , field involve &gt; 10 % bone marrow reserve ) . 2 . Phase 2 ONLY : Subject prior chemotherapy , radiotherapy , investigational anticancer agent biologic therapy disease study . Single nontarget lesion irradiation intent symptom palliation allow ≥ 4 week prior Cycle 1 Day 2 . 3 . Subject current central nervous system ( CNS ) leptomeningeal metastasis history CNS leptomeningeal metastasis . 4 . Subject history seizure within 12 month Cycle 1 Day2 diagnose neurological condition place subject increase risk seizure . 5 . Subject receive anticancer Chinese medicine anticancer herbal remedy within 14 day prior Cycle 1 Day2 . 6 . Subject major surgery within 6 week prior Cycle 1 Day2 ( subject must completely recover previous surgery prior Cycle 1 Day2 ) . 7 . Subject clinically significant uncontrolled major medical condition ( ) include limited : Uncontrolled nausea/vomiting/diarrhea ; Active uncontrolled infection ; History hepatitis B ( HBV ) surface antigen ( HBsAg ) positivity within 3 month prior date inform consent study ( test perform within 3 month , must do screening ) ; History hepatitis C ( HCV ) HCV RNA positivity within 3 month prior date inform consent study ( test perform within 3 month must do screening ) ; Symptomatic congestive heart failure ( NYHA class ≥ II ) ; Unstable angina pectoris cardiac arrhythmia ( except atrial fibrillation ) ; Psychiatric illness/social situation would limit compliance study requirement ; Any medical condition , opinion Investigator , place subject unacceptably high risk toxicity . 8 . The subject history another active cancer within past 3 year except cervical cancer situ , situ carcinoma bladder , squamous basal cell carcinoma skin another situ cancer consider cured investigator ( e.g. , situ prostate cancer , breast DCIS ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Veliparib</keyword>
	<keyword>PARP - Poly ( ADP ) ribose polymerase</keyword>
	<keyword>ABT-888</keyword>
	<keyword>Extensive Stage Smal Cell Lung Cancer</keyword>
</DOC>